Addiction

SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV,...

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment

Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite...

Sibannac, Inc. Gearing up for Revenue Through Its White-Label Manufacturing, Wholesale Distribution and Opening of Its First Retail Location

Scottsdale, Arizona--(Newsfile Corp. - November 13, 2023) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the...

Bicycle Health Partners with Override Health to Establish Patient Referral Relationship, Increasing Access to Specialists in Chronic Pain Care and Opioid Use Disorder Treatment

More than one-in-five patients seeking treatment for chronic pain are prescribed opioids at their initial visit, contributing to an opioid...

Küleon Bioscience Announces Scientific Breakthrough with First Known ”Trifunctional” 5-HT2C Receptor Agonist that is also a Full Antagonist of the 5-HT2A and 5-HT2B Receptors, Creating an Exciting Lead for Multiple Neuropsychiatric Illnesses

error: Content is protected !!